Vericel Corporation (VCEL) News
Filter VCEL News Items
VCEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VCEL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VCEL News From Around the Web
Below are the latest news stories about VERICEL CORP that investors may wish to consider to help them evaluate VCEL as an investment opportunity.
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Cor |
Vericel price target raised to $67 from $61 at TruistTruist analyst Richard Newitter raised the firm’s price target on Vericel (VCEL) to $67 from $61 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, s |
High Growth Tech Stocks to Watch in December 2024Over the last 7 days, the United States market has remained flat, but it has risen by an impressive 28% over the past year, with earnings projected to grow by 15% annually in the coming years. In this environment, high growth tech stocks that demonstrate strong revenue potential and innovative capabilities are particularly noteworthy for investors seeking opportunities in a dynamic sector. |
High Growth Tech Stocks To Explore In November 2024The United States market has experienced a notable upswing, climbing 3.9% over the last week and 33% over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions. |
Vericel Stock Sees RS Rating Shoot HigherA Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue? |
Vericel Third Quarter 2024 Earnings: Beats ExpectationsVericel ( NASDAQ:VCEL ) Third Quarter 2024 Results Key Financial Results Revenue: US$57.9m (up 27% from 3Q 2023). Net... |
Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ...Vericel Corp (VCEL) reports a 27% revenue increase and strategic advancements, positioning for sustained growth despite rising expenses. |
Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue EstimatesVericel (VCEL) delivered earnings and revenue surprises of 60% and 4.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Vericel Reports Third Quarter 2024 Financial ResultsTotal Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarte |
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |